Topic: Eli Lilly and Company

Why You Just Got Hammered

The headline on Celldex Therapeutics' (Nasdaq: CLDX) press release sounds rather promising: "Celldex Therapeutics Regains Worldwide Rights to...
Almost half of Americans took at least one prescription drug per month in 2008, an increase of 10 percent over the past decade, a U.S. study found...
Part IV in a series on Medicine's Suicide Problem. Part I is HERE, Part II is HERE, and part III is HERE.). . Psychiatrist Arif Khan has spent...
Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention...
Sun Pharmaceutical Industries Ltd. ed New Drug Application (ANDA) to market a generic version of Strattera , atomoxetine hydrochloride capsules....
A federal appeals court on Wednesday affirmed an injunction blocking generic versions of Eli Lilly & Co.'s osteoporosis drug Evista. . . Teva...
Aaron Lynett/National Post. A scale model of North America's tallest flagpole that will be constructed in Emery Village sits in the office of City...
Eli Lilly & Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention deficit hyperactivity drug Strattera.The U.S. District Court for the District of New Jersey ruled against the company, saying its ...
Indianapolis-based Lilly Endowment says assets drop 7 percent to $5.3 billion at end of 2009The assets of the Lilly Endowment fell 7 percent to $5.3 billion at the end of last year as the foundation remains heavily invested in the ...

Lilly profit tops views, but reform hits results

NEW YORK (Reuters) - Eli Lilly and Co <LLY.N> posted a better-than-expected first-quarter profit on Monday, although it warned that costs from the newly passed health reform law would crimp results for the year.The drugmaker said the outlook